Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007:4:13-8.
Epub 2007 May 12.

Imaging in clinical trials

Bradley J Erickson  1 , Jan C Buckner
Affiliations

Imaging in clinical trials

Bradley J Erickson et al. Cancer Inform. 2007.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Number of submissions of new molecular entities (NMEs) and biologics license application (BLA) to FDA over the past 10 years. (U.S. Department of Health and Human Services-Food and Drug Administration 2004)
Figure 2
Figure 2
The cost of developing a successful compound is increasing, and the clinical trials pieces are the rapidly increasing components (Windhover’s In Vivo 2003).
See this image and copyright information in PMC

References

    1. DICOM Standards Committee The DICOM Standard http://medical.nema.org
    1. DiMasi J. “The value of improving the productivity of the drug development process: faster times and better decisions”. Pharmacoeconmics. 2002;20(Suppl 3):1–10. - PubMed
    1. Jaffe C. Philadelphia, PA.: 2005. “Imaging at NCI”. c. i. v. I. Workspace.
    1. Kothari M, Guermazi A, et al. “Imaging in antiangiogenesis trial: a clinical trials radiology perspective”. British Journal Radiology. 2003;76:92–96. - PubMed
    1. Mills G. Regulatory Opportunities & Challenges of Imaging as a Drug Development Tool. 2005. http://www.fda.gov/cder/regulatory/med-Imaging/imagingKeyNote.ppt#259,3,FDA Critical Path Initiative, FDA.

LinkOut - more resources